18F-FDG primary tumor uptake to improve N status prediction in cT1 non-metastatic non-small cell lung cancer: development and validation of a positron emission tomography model.

FDG NSCLC lymph nodes model positron emission tomography

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2023
Historique:
received: 10 01 2023
accepted: 03 04 2023
pubmed: 14 5 2023
medline: 14 5 2023
entrez: 14 5 2023
Statut: epublish

Résumé

Occult lymph node involvement is a major issue in the management of non-small cell lung carcinoma (NSCLC), with an estimated prevalence of approximately 2.9-21.6% in 18F-FDG PET/CT series. The aim of the study is to construct a PET model to improve lymph node assessment. Patients with a non-metastatic cT1 NSCLC were retrospectively included from two centers, one used to constitute the training set, the other for the validation set. The best multivariate model based on Akaike's information criterion was selected, considering age, sex, visual assessment of lymph node (cN0 status), lymph node SUVmax, primary tumor location, tumor size, and tumoral SUVmax (T_SUVmax). A threshold minimizing false pN0 prediction was chosen. This model was then applied to the validation set. In total, 162 patients were included (training set: 44, validation set: 118). A model combining cN0 status and T_SUVmax was selected (AUC 0.907, specificity at threshold: 88.2%). In the validation cohort, this model resulted in an AUC of 0.832 and a specificity of 92.3% versus 65.4% for visual interpretation alone ( Primary tumor SUVmax improves N status prediction and could allow a better selection of patients who are candidates for minimally invasive approaches.

Identifiants

pubmed: 37181374
doi: 10.3389/fmed.2023.1141636
pmc: PMC10169590
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1141636

Informations de copyright

Copyright © 2023 Morland, Chiappetta, Falcoz, Chenard, Annunziata, Boldrini, Lococo and Imperiale.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

David Morland (D)

Médecine Nucléaire, Institut Godinot, Reims, France.
CReSTIC EA 3804 et Laboratoire de Biophysique, Université de Reims Champagne-Ardenne, Reims, France.
Unità di Medicina Nucleare, GSTeP Radiofarmacia, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Marco Chiappetta (M)

Università Cattolica del Sacro Cuore, Rome, Italy.
Chirurgia Toracica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Pierre-Emmanuel Falcoz (PE)

Service de Chirurgie Thoracique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Marie-Pierre Chenard (MP)

Service de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Salvatore Annunziata (S)

Unità di Medicina Nucleare, GSTeP Radiofarmacia, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Luca Boldrini (L)

Unità di Radioterapia, Radiomics, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Filippo Lococo (F)

Università Cattolica del Sacro Cuore, Rome, Italy.
Chirurgia Toracica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Alessio Imperiale (A)

Médecine Nucléaire, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Hôpitaux Universitaires de Strasbourg, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.
DRHIM, IPHC, UMR7178, CNRS/Unistra, Strasbourg, France.

Classifications MeSH